Top-Rated StocksTop-RatedNASDAQ:NEO NeoGenomics (NEO) Stock Price, News & Analysis $16.04 -0.17 (-1.05%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$15.89▼$16.3550-Day Range$13.40▼$17.7352-Week Range$11.03▼$21.22Volume477,869 shsAverage Volume818,331 shsMarket Capitalization$2.05 billionP/E RatioN/ADividend YieldN/APrice Target$19.89 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get NeoGenomics alerts: Email Address NeoGenomics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.90 Rating ScoreUpside/Downside24.0% Upside$19.89 Price TargetShort InterestBearish3.93% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.22) to ($0.07) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.46 out of 5 starsMedical Sector866th out of 910 stocksTesting Laboratories Industry2nd out of 2 stocks 2.5 Analyst's Opinion Consensus RatingNeoGenomics has received a consensus rating of Moderate Buy. The company's average rating score is 2.90, and is based on 9 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageNeoGenomics has only been the subject of 3 research reports in the past 90 days.Read more about NeoGenomics' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted3.93% of the outstanding shares of NeoGenomics have been sold short.Short Interest Ratio / Days to CoverNeoGenomics has a short interest ratio ("days to cover") of 6.6.Change versus previous monthShort interest in NeoGenomics has recently increased by 2.87%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldNeoGenomics does not currently pay a dividend.Dividend GrowthNeoGenomics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NEO. Previous Next 0.0 News and Social Media Coverage MarketBeat FollowsOnly 2 people have added NeoGenomics to their MarketBeat watchlist in the last 30 days. This is a decrease of -60% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, NeoGenomics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.30% of the stock of NeoGenomics is held by insiders.Percentage Held by Institutions98.50% of the stock of NeoGenomics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about NeoGenomics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for NeoGenomics are expected to grow in the coming year, from ($0.22) to ($0.07) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of NeoGenomics is -24.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of NeoGenomics is -24.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNeoGenomics has a P/B Ratio of 2.24. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about NeoGenomics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad True Gold RepublicChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a population of over 1.4 BILLION is “buying gold like there’s no tomorrow,” according to The New York Times. China, a rising global economic threat, aims to reduce its dependence on the US dollar… . Click here now to get your free 'De-Dollarization' Guide. About NeoGenomics Stock (NASDAQ:NEO)NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.Read More NEO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NEO Stock News HeadlinesAugust 29, 2024 | businesswire.comNeoGenomics to Participate in the Morgan Stanley 22nd Annual Global Healthcare ConferenceAugust 28, 2024 | americanbankingnews.comNeoGenomics, Inc. (NASDAQ:NEO) Given Average Recommendation of "Moderate Buy" by BrokeragesSeptember 7, 2024 | Sasco Gold LLC (Ad)Say Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." I believe the American people deserve to control the fate of their own life savings which is why I had my team put together our latest guide to protect your hard-earned wealth before it's too late... August 18, 2024 | finance.yahoo.comNEO Sep 2024 12.500 put (NEO240920P00012500)August 18, 2024 | finance.yahoo.comNEO Sep 2024 12.500 call (NEO240920C00012500)August 12, 2024 | nz.finance.yahoo.comDeltaShares S&P 600 Managed Risk ETF (DMRS)July 31, 2024 | msn.comFort Myers-based NeoGenomics reports 2Q results, updates financial outlook for 2024July 31, 2024 | markets.businessinsider.comStrong Buy Recommendation for NeoGenomics Amidst Operational Efficiency and Growth PotentialSeptember 7, 2024 | Sasco Gold LLC (Ad)Say Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." I believe the American people deserve to control the fate of their own life savings which is why I had my team put together our latest guide to protect your hard-earned wealth before it's too late... July 31, 2024 | seekingalpha.comNeoGenomics, Inc. (NEO) Q2 2024 Earnings Call TranscriptJuly 31, 2024 | markets.businessinsider.comBuy Rating Affirmed for NeoGenomics Amid Solid Sales Growth and Expanding MarginsJuly 31, 2024 | markets.businessinsider.comBuy Rating Reiterated for NeoGenomics Amidst Strong Financial Performance and Market PositioningJuly 31, 2024 | msn.comNeoGenomics, Inc. (NASDAQ:NEO) Q2 2024 Earnings Call TranscriptJuly 29, 2024 | seekingalpha.comNeoGenomics, Inc. 2024 Q2 - Results - Earnings Call PresentationJuly 29, 2024 | finance.yahoo.comNeoGenomics Reports Second Quarter 2024 ResultsJuly 28, 2024 | markets.businessinsider.comNeogenomics earnings preview: what Wall Street is expectingJuly 26, 2024 | finance.yahoo.comWorldwide Liquid Biopsy (LBx) Market Forecasted to Grow at 29% p.a., Reaching $10.1B by 2029 – Market Report by DeciBio Consulting LLCJuly 23, 2024 | ca.finance.yahoo.comNEO Aug 2024 20.000 putSee More Headlines Receive NEO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NeoGenomics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings7/29/2024Today9/07/2024Next Earnings (Estimated)11/04/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Testing laboratories Sub-IndustryBusiness Services Current SymbolNASDAQ:NEO CUSIPN/A CIK1077183 Webwww.neogenomics.com Phone(239) 768-0600Fax239-690-4237Employees2,100Year Founded2002Price Target and Rating Average Stock Price Target$19.89 High Stock Price Target$26.00 Low Stock Price Target$17.00 Potential Upside/Downside+24.0%Consensus RatingModerate Buy Rating Score (0-4)2.90 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)($0.66) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-87,970,000.00 Net Margins-12.50% Pretax Margin-13.28% Return on Equity-2.72% Return on Assets-1.53% Debt Debt-to-Equity Ratio0.37 Current Ratio2.01 Quick Ratio1.93 Sales & Book Value Annual Sales$628.25 million Price / Sales3.26 Cash Flow$0.27 per share Price / Cash Flow58.52 Book Value$7.15 per share Price / Book2.24Miscellaneous Outstanding Shares127,712,000Free Float126,052,000Market Cap$2.05 billion OptionableOptionable Beta1.18 Social Links 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesMr. Christopher Michael Smith BSc (Age 61)CEO & Director Comp: $2.86MMr. Jeffrey S. Sherman M.B.A. (Age 58)Chief Financial Officer Comp: $1.17MMr. Vishal Sikri (Age 48)President of Advanced Diagnostics Comp: $1.08MMs. Melody Harris Esq. (Age 57)J.D., President & COO of Informatics Comp: $1.4MMr. Warren Stone (Age 51)Chief Commercial Officer Comp: $1.42MMs. Kendra SweeneyVice President of Investor Relations & CommunicationsMs. Alicia Olivo (Age 40)Executive VP of Business Development, General Counsel & Corporate Secretary Mr. Hutan Hashemi J.D. (Age 45)Chief Compliance Officer Dr. Derek Lyle M.D.Chief Medical OfficerMr. Gary PassmanChief Culture OfficerMore ExecutivesKey CompetitorsHealthEquityNASDAQ:HQYBilibiliNASDAQ:BILIEtsyNASDAQ:ETSYQXONASDAQ:QXOTriNet GroupNYSE:TNETView All CompetitorsInsiders & InstitutionsTruist Financial CorpSold 4,699 shares on 8/21/2024Ownership: 0.028%Point72 Asset Management L.P.Sold 1,165,943 shares on 8/19/2024Ownership: 0.808%Susquehanna International Group LLPSold 72,700 shares on 8/16/2024Ownership: 0.000%Algert Global LLCBought 12,843 shares on 8/16/2024Ownership: 0.021%Northwestern Mutual Wealth Management Co.Sold 1,613 shares on 8/16/2024Ownership: 0.004%View All Insider TransactionsView All Institutional Transactions NEO Stock Analysis - Frequently Asked Questions How have NEO shares performed this year? NeoGenomics' stock was trading at $16.18 at the beginning of the year. Since then, NEO shares have decreased by 0.9% and is now trading at $16.04. View the best growth stocks for 2024 here. How were NeoGenomics' earnings last quarter? NeoGenomics, Inc. (NASDAQ:NEO) issued its quarterly earnings results on Monday, July, 29th. The medical research company reported $0.03 EPS for the quarter, beating the consensus estimate of $0.00 by $0.03. The business's quarterly revenue was up 12.0% on a year-over-year basis. What is Douglas M. VanOort's approval rating as NeoGenomics' CEO? 116 employees have rated NeoGenomics Chief Executive Officer Douglas M. VanOort on Glassdoor.com. Douglas M. VanOort has an approval rating of 98% among the company's employees. This puts Douglas M. VanOort in the top 20% of approval ratings compared to other CEOs of publicly-traded companies. Does NeoGenomics have any subsidiaries? The following companies are subsidiaries of NeoGenomics: Inivata Limited, Trapelo Health, Genesis Acquisition Holding Corp, Genoptix, Clarient Inc, GE Medical Holding AB., Path Labs LLC, and others. Who are NeoGenomics' major shareholders? Top institutional investors of NeoGenomics include First Light Asset Management LLC (2.96%), Dimensional Fund Advisors LP (2.60%), American Century Companies Inc. (2.55%) and Emerald Advisers LLC (1.44%). Insiders that own company stock include Alicia C Olivo, William Bonello, Mark Mallon, Douglas Matthew Brown and Kathryn B Mckenzie. View institutional ownership trends. How do I buy shares of NeoGenomics? Shares of NEO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of NeoGenomics own? Based on aggregate information from My MarketBeat watchlists, some other companies that NeoGenomics investors own include Marvell Technology (MRVL), NVIDIA (NVDA), Alibaba Group (BABA), Block (SQ), Inseego (INSG), PayPal (PYPL) and Micron Technology (MU). This page (NASDAQ:NEO) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NeoGenomics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NeoGenomics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
